Dr. Reddys Laboratories Ltd.

US-based drug maker AbbVie Inc, the spun-off entity of Abbott, has sued Dr Reddys Laboratories for purportedly infringing the former’s patented drug Zemplar on six counts, concerning three patents. AbbVie has demanded the court to pass an order to hold back Dr Reddys from commercially manufacturing, using, offering for sale, selling, marketing, distributing, or importing Dr Reddys' generic paricalcitol injectable products prior to the expiration of said patents.

Earlier, Dr Reddys filed an ANDA (Abbreviated New Drug Application) with the US Food and Drug Administration (US FDA), seeking approval to sell a generic copy of US drug maker’s Zemplar injectable products in 2 microgram/ml and 5 microgram/ml formulations, prior to the expiration of the patents owned by and exclusively licensed to the complainants.